Published in Cancer Weekly, February 3rd, 2004
INB and IFCP will jointly research, develop, and test compounds for anticarcinogenic activity. Under the agreement, INB has the exclusive rights to commercialize the compounds resulting from the research and development collaboration. The Institute will receive a royalty for each compound commercialized by INB as a result of the collaboration.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.